title: Ex vivo expansion CD34+/AC133+-selected autologous peripheral blood progenitor cells (PBPC) in high-risk breast cancer patients receiving intensive chemotherapy.
abstract: AC133 antibody provides an alternative to CD34 for the selection and characterization of cells necessary for engraftment in transplant situations. We studied the effect of stem cell factor (SCF), interleukin 3 (IL-3) and interleukin 11 (IL-11) on the ex vivo expansion of human CD34+/AC133+ progenitors isolated from leukapheresis products from chemotherapy plus granulocyte-colony-stimulating factor (G-CSF) -mobilized adult donors. MiniMACS AC133+ isolated cells contained a mean of 85% (80-90) AC133+ cells. Enriched AC133+ cells co-expressed CD34+ 80%, CD71low 36.6% and CD33+ 6.6%. After a seven-day ex vivo expansion in the presence of SCF + IL-3 + IL-11, the number of cells increased 19 times. These cells expressed a mean 12% CD34+ and 74% CD71+ (23% CD 71high) and 59% CD33+. This means that the absolute number of CD34+ cells increased slightly, the number of CD33+ increased 100 times and cells with high density CD71high (23%) appeared. These cells represent the cells committed to erythroid differentiation. The increase in the number of CFU-GM with various combinations of cytokines SCF + Il-3 + IL-11 will be discussed. The number of CFU-GM in culture after a seven-day ex vivo expansion in the presence of SCF + IL-3 + IL-11 increased 45 times.
authors.affiliation: Institute of Radiobiology and Immunology, Purkyne Military Medical Academy, Hradec Králové, Czech Republic.
authors.forename: J
authors.initials: J
authors.lastname: Vávrová
authors.forename: S
authors.initials: S
authors.lastname: Filip
authors.forename: D
authors.initials: D
authors.lastname: Vokurková
authors.forename: M
authors.initials: M
authors.lastname: Bláha
authors.forename: J
authors.initials: J
authors.lastname: Vanásek
authors.forename: L
authors.initials: L
authors.lastname: Jebavý
mesh_terms: D000071916:AC133 Antigen; D000328:Adult; D015703:Antigens, CD; D018952:Antigens, CD34 / Q000097:blood*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002455:Cell Division / Q000187:drug effects; D003520:Cyclophosphamide / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006023:Glycoproteins / Q000097:blood*; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000276:immunology*; D006801:Humans; D007279:Injections, Subcutaneous; D017370:Interleukin-11 / Q000494:pharmacology; D007377:Interleukin-3 / Q000494:pharmacology; D008875:Middle Aged; D010455:Peptides / Q000097:blood*; D019089:Stem Cell Factor / Q000494:pharmacology
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; D018952:Antigens, CD34; D006023:Glycoproteins; D017370:Interleukin-11; D007377:Interleukin-3; C000606023:PROM1 protein, human; D010455:Peptides; D019089:Stem Cell Factor; D015251:Epirubicin; D003520:Cyclophosphamide